# A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients

> **NCT03423186** · PHASE1,PHASE2 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 6 (actual)

## Conditions studied

- Sanfilippo Syndrome Type A (MPS IIIA)

## Interventions

- **DRUG:** SOBI003

## Key facts

- **NCT ID:** NCT03423186
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-10-25
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03423186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03423186, "A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03423186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*